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Introduction
Although cardiovascular disease (CVD) has been one of the 
leading causes of death in most developed countries, the rates of 
morbidity and mortality associated with CVD have been steadily 
decreasing during the recent decades. On the contrary, the rates of 
morbidity and mortality related to CVD have been rapidly increasing 
in Korea.1)2) Considering that the rates of other risk factors are being 
reduced and more controlled than before, this might be mainly due 
to the unhealthy lifestyle of Koreans and the associated disease of 
dyslipidemia. For Koreans, therefore, lifestyle modification and the 
management of dyslipidemia are very important in order to prevent 
CVD or its recurrence.
The Korean Society of Lipidology and Atherosclerosis and other 
related societies and organizations came together and formed the 
Committee for the Guidelines for the Management of Dyslipidemia, 
to provide opinions for the proper management of dyslipidemia with 
the aim of preventing CVDs in Korea. We published the first edition 
of the Guidelines for the Management of Dyslipidemia in 1996 
and the second edition in 2003. New guidelines for dyslipidemia 
management were published in Europe (2011) and in the United 
States (2013), on the basis of the most recent research results.3)4) In 
this regard, 18 related societies and organizations in Korea gathered 
to suggest new guidelines for dyslipidemia management.
Appropriate guidelines should be established on the basis of 
individual evaluations of the future risks of CVD and death. This 
risk evaluation is possible only if the potential risk factors can 
be accurately estimated in a representative Korean population 
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followed up for a long term and, at the same time, if the rates 
of CVD and death are precisely recorded. Although several studies 
have been published in Korea, it might be difficult to apply the 
results to actual clinical practice owing to the lack of the above-
mentioned elements.5) In addition, it is not possible to quote 
Western risk evaluation criteria, as the mortality of ischemic heart 
disease in Korea is among the lowest worldwide. 
In this background, we adopted the previous approach, instead 
of following the trends of overseas treatment guidelines. There is 
a desperate need, at this time, for a study to evaluate the risk of 
CVD in Koreans. In addition, almost all studies on the management 
of dyslipidemia are from Western countries, and a review of 
those studies is necessary to determine whether such results can 
be applicable to Koreans. The grade of recommendation and the 
evidence level in this treatment guideline were quoted from the 
treatment guidelines of the American College of Cardiology and 
the American Heart Association (ACC/AHA).4) For more details, it 
would be helpful to see the full text, which will be published along 
with a summary.
Korean guidelines for management of dyslipidemia were made 
in full text and in executive summary. And this is the English 
translation version of the executive summary. This treatment 
guideline was based on observatory studies that investigated the 
preventive effects of dyslipidemia management. Therefore, it does 
not mean that this guideline should be applied to all patients with 
dyslipidemia. Instead, physicians should make their final decision 
about how to treat their patients on the basis of the clinical 
judgments. 
Chapter 1. Epidemiology of Dyslipidemia in Koreans
1. Current status of cardiovascular disease in Korea
Annually, 17000000 people die of CVD worldwide, which 
accounts for 30% of all deaths.6) In Korea as well, CVD is one of 
the leading causes of death, where the mortality of coronary artery 
disease (CAD) was 31 per 100000 males and 27 per 100000 females 
in 2012 (Fig. 1-1), whereas the mortality of cerebrovascular diseases 
was 49 per 100000 males and 53 per 100000 females in the 
same year (Fig. 1-2). Nevertheless, mortality from cerebrovascular 
diseases has greatly decreased since the 1990s, whereas that 
from coronary artery disease (CAD) has recently begun to slightly 
decrease when adjusted for age (Fig. 1-1). 
For cerebrovascular diseases, whereas more people died of 
cerebral hemorrhage (nontraumatic intracerebral hemorrhage and 
subarachnoid hemorrhage) before 2002, death due to cerebral 
infarction (ischemic stroke) predominated since 2002 (Fig. 1-3). 
This might be due to the improved management of blood pressure, 
thereby reducing events of cerebral hemorrhage, and the better 
treatment for cerebral hemorrhage. 
Compared with the mortality data, it is difficult to identify such 
changes in the prevalence and incidence rate of CVD, owing to the 
lack of nation-wide statistics. 
The Korea National Health and Nutritional Examination Survey 
(KNHANES) reported that 3% of the population ≥30 years old 
experience stroke. Concerning CAD, the prevalence rate of ˂1% 
in 1998 has increased up to 2.5% in 2010.7) It is difficult to 
note changes in the incidence rate of CVD owing to the lack of 
Age-adjusted mortality (based on population 2005)Age-unadjusted mortality



















Fig. 1-1. Trends of coronary artery disease mortality in Korea.
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a nation-wide continuous monitoring system, however, recent 
research estimated that the annual incidence rate of acute 
myocardial infarction (AMI) was about 50 cases per 100000 
males and about 20 cases per 100000 females.8) The incidence 
rate of cerebrovascular diseases depends on the type (i.e., cerebral 
infarction or cerebral hemorrhage), such that the incidence rate of 
cerebral hemorrhage is expected to decline rapidly, whereas that 
of cerebral infarction is expected to gradually increase. Therefore, 
the number of patients with cerebral infarction is expected to be 
greater than the number of patients with cerebral hemorrhage. The 
difference in the incidence of CVD according to the geographic 
region and year is predominantly explained by the change in the 
distribution of cardiovascular risk factors. The prevalences of 
diabetes and dyslipidemia are increasing, whereas there has not 
been much change in the prevalence of hypertension and the rate 
of smoking cessation in Korea. Therefore, CAD is expected to be the 
most prevalent type of CVD in Korea.
2. Risk factors and risk evaluation of cardiovascular disease 
in Korea
Knowing a person’s cardiovascular risk factors is very important 
in terms of both prevention and management; however, each 
method of risk factor evaluation is different depending on the 
country-specific treatment guidelines. In 2009, the presence of 
a history of existing CAD or its equivalent risk factors, including 
Cerebral hemorrhageCerebral infarction









Fig. 1-3. Changes in the number of death due to cerebral hemorrhage and cerebral infarction. 
Age-adjusted mortality (based on population 2005)Age-unadjusted mortality



















Fig. 1-2. Trends of cerebrovascular disease mortality in Korea.
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carotid artery disease, peripheral artery disease (PAD), abdominal 
aneurysm, and diabetes, was defined as high risk, according to the 
revised Korean Guidelines for the Management of Dyslipidemia. 
Moreover, according to the revised National Cholesterol Education 
Program Adult Treatment Panel III (NCEP-ATP III) guidelines of 
treatment in 2004, risks were scored on the basis of the number of 
cardiovascular risk factors such as nonsmoking rate, hypertension, 
low high-density lipoprotein (HDL) cholesterol, age, and family 
history of premature CAD. Persons with two or more risk factors 
were classified as the intermediate risk group, whereas those with 
none or only one risk factor were classified as the low-risk group.9)
From 1996 through to 2004 in Korea, the Korean Heart Study, on 
430920 male and female subjects who participated in nationwide 
health check-ups in 18 health promotion centers, was conducted. 
In this study, the observation of the incidence and risk factors for 
cerebrovascular diseases was followed for 10 years. The study results 
showed that the most influential risk factors on cerebrovascular 
diseases were hypertension, nonsmoking status, and dyslipidemia 
in male patients, and hypertension, dyslipidemia, diabetes, and 
nonsmoking status in female patients.5) In addition, the relative 
risk, which describes the risk of incident CVD or cerebrovascular 
diseases, of each risk factor was analyzed. The results showed that 
the association of smoking and dyslipidemia with CAD was stronger 
than that with cerebrovascular diseases, whereas the association of 
hypertension with cerebrovascular diseases was greater than that 
with CADs. Total cholesterol levels ≥200 mg/dL increased the risk of 
CAD, compared with levels <200 mg/dL, and increased the levels of 
HDL cholesterol, resulting in the risk of both CVD and cerebrovascular 
diseases. Overall, the Korean-specific risk factors for CVD included 
hypertension, smoking, dyslipidemia, and diabetes, all of which 
are similar to those from other countries, and a Korea-specific, 
10-year CAD risk-scoring system based on these established risk 
Table 1-1. Trends of serum lipid profiles in subjects ≥19 years (unit: mg/dL) in Korea 
Type n Average Standarderror 
Percentile
5 10 25 50 75 90 95
Total cholesterol 　 　 　
Male 2005 2279 183.3 (0.9) 131 142 159 181 205 227 242 
2007-2009 6836 185.4 (0.6) 133 143 161 183 207 232 246 
2010-2012 7296 187.7 (0.6) 133 143 163 186 210 233 249 
Female 2005 3096 182.7 (0.8) 133 142 158 179 204 228 242 
2007-2009 9254 186.7 (0.5) 135 144 161 183 208 234 251 
2010-2012 9765 188.6 (0.5) 136 145 163 185 210 236 254 
LDL cholesterol 　 　 　
Male 2007-2009 6596 111.0 (0.5) 63.6 74.0 89.8 109.5 130.3 150.8 163.3 
2010-2012 7056 112.2 (0.5) 63.0 73.0 90.0 110.7 132.2 152.9 165.6 
Female 2007-2009 9155 113.8 (0.4) 68.6 77.0 91.4 110.6 132.7 155.3 169.6 
2010-2012 9680 114.5 (0.4) 68.3 77.1 92.1 111.6 133.7 156.0 170.4 
HDL cholesterol 　 　 　
Male 2007-2009 6836 45.5 (0.2) 32.1 33.9 38.2 44.3 51.3 59.1 63.8 
2010-2012 7296 46.5 (0.2) 32.1 34.7 39.1 45.2 52.2 60.1 65.2 
Female 2007-2009 9254 50.7 (0.2) 34.7 37.3 42.8 49.5 57.4 65.2 70.5 
2010-2012 9765 51.9 (0.2) 35.4 38.2 43.9 51.3 58.3 67.0 72.2 
Triglycerides 　 　 　
Male 2005 2280 155.7 (3.7) 52 61 84 121 181 269 353 
2007-2009 5030 150.6 (1.9) 52 61 83 120 179 265 346 
2010-2012 5866 153.3 (2.1) 49 59 83 122 183 268 343 
Female 2005 3096 110.9 (1.6) 45 53 66 91 129 192 241 
2007-2009 7382 113.4 (1.2) 40 48 64 92 138 200 255 
2010-2012 8402 112.0 (1.0) 40 47 64 92 137 198 250 
LDL: low density lipoprotein, HDL: high density lipoprotein
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factors is also currently available. However, validation of this scoring 
system and the indication for lipid-lowering medications according 
to the scored risks, as well as further study are needed to provide 
appropriate treatments for the Korean population.
3. Distribution of serum lipid profile in Koreans
The average serum levels of total cholesterol in Korean male 
adults (age, ≥20 years) were 183 mg/dL in 2005, 188 mg/dL in 
2010–2012, 183 mg/dL in 2005, and 189 mg/dL between 2010 and 
2012. The levels have been increasing by about 5–6 mg/dL for the 
last 7 years between 2005 and 2012.
By contrast, between 2010 and 2012, the average triglyceride 
levels were 153 mg/dL in males and 112 mg/dL in females, exhibiting 
much less variability compared with the total cholesterol levels. 
During this period, the serum levels of low-density lipoprotein 
(LDL) cholesterol averaged 112 mg/dL in males and 115 mg/dL in 
females, whereas the levels of HDL cholesterol averaged 47 mg/dL 
in males and 52 mg/dL in females, thereby making the increment 
approximately 1 mg/dL for both LDL and HDL cholesterol levels, 
compared with the period between 2007 and 2009 (Table 1-1).1)
For adults older than 30 years, the prevalence of 
hypercholesterolemia (2010–2012) was 12.6% in males and 
14.9% in females, which increased by 5.4% in males and by 6.5% 
in females during a 7-year period since 2005. By age group, the 
prevalence rate was highest in males in their 50s and females in 
their 60s (16.9% and 32.2%, respectively). 
The prevalence rates of hypertriglyceridemia, defined by a total 
cholesterol level of ≥240 mg/dL or taking lipid-lowering agents 
(2010–2012), were 22.9% in males and 10.4% in females, with 
no significance difference from those in 2005. However, when 
specified by sex, the prevalence rate was two-fold higher in males 
than in females. By age, the highest prevalence rates were observed 
in males in their 50s (28.3%) and females in their 60s (17.5%).1) 
From 2010 through to 2012, the awareness rate of 
hypercholesterolemia was 45.2% in males and 49.1% in females, 
whereas the treatment rate was 35.8% in males and 38.4% in females, 
both of which increased by approximately 20% compared with 
those in 2005. The proportion of controlled hypercholesterolemia 
was about 30%, whereas that of treated patients was approximately 
80%, which increased by ≥15% compared with that in 2005. In 
comparison by sex, the awareness and treatment rates of female 
patients were slightly higher than those of male patients. By age 
group, the awareness rate and treatment rate in subjects in their 
30s–40s were 25% and 15%, respectively, which were much lower 
than those in the other age groups (Table 1-2).1)
Chapter 2. Criteria for the Diagnosis and Treatment 
of Dyslipidemia
1. Evaluation of laboratory lipid and diagnostic criteria
For the screening of dyslipidemia in persons ≥20 years old, testing 
of fasting serum lipid levels (total cholesterol, triglycerides, HDL 
cholesterol, and LDL cholesterol) is recommended every 4–6 years.10) 
















Awareness rate 157 24.4 (4.2) 604 37.0 (2.2) 850 45.2 (2.3) <0.0001
Treatment rate 157 17.5 (3.6) 604 24.6 (1.9) 850 35.8 (2.0) <0.0001 
Control rate (total patients) 157 11.0 (2.5) 604 20.2 (1.7) 850 28.7 (1.8) <0.0001 
Control rate (treated patients) 32 63.1 (11.0) 167 80.6 (3.3) 367 79.3 (2.8) 0.1810 
Female
Awareness rate 237 23.8 (3.0) 1098 40.3 (1.8) 1532 49.1 (1.7) <0.0001
Treatment rate 237 17.1 (2.6) 1098 28.6 (1.6) 1532 38.4 (1.8) <0.0001 
Control rate (total patients) 237 10.6 (2.2) 1098 20.3 (1.4) 1532 30.9 (1.6) <0.0001
Control rate (treated patients) 45 61.8 (7.9) 336 68.8 (2.9) 647 78.5 (1.9) 0.0041
Awareness rate: percentile of patients with a diagnosis of hypercholesterolemia among the total patients with hypercholesterolemia. Treatment rate: 
percentile of hypercholesterolemia patients who are currently taking cholesterol-lowering drugs for >20 days/month. Control rate (total patients): percentile 
of hypercholesterolemia patients with a total cholesterol level <200 mg/dL among the total patients with hypercholesterolemia. Control rate (treated patients): 
percentile of hypercholesterolemia-treated patients with total cholesterol level <200 mg/dL among the total patients with hypercholesterolemia
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To acquire the triglyceride and LDL cholesterol levels among the 
lipid profiles, fasting for at least 9–12 h before venous sampling is 
required. The subject should be relaxed in the sitting position for at 
least 5 min before venous sampling, to avoid hemoconcentration 
due to excessive movement. Collecting tubes without an 
anticoagulant is recommended for serum samples, and EDTA tubes 
are recommended for plasma samples. When plasma samples are 
used for analyses, the results are generally lower by approximately 
3% than those for serum samples.11)
Generally, the LDL cholesterol levels can be mathematically 
estimated, by using the fasting levels of total cholesterol, 
triglycerides and HDL cholesterol. If the triglyceride level is ≤400 
mg/dL, it can be divided by 5 to estimate the level of very low 
density lipoprotein (VLDL) cholesterol. As the total cholesterol is the 
sum of LDL cholesterol, HDL cholesterol, and VLDL cholesterol, the 
value of LDL cholesterol concentration can be calculated according 
to the following Friedewald formula:
However, if a subject has a triglyceride level of >400 mg/dL, the 
mathematically estimated level of LDL cholesterol with the formula 
suggested above will be significantly lower than its actual value. 
Therefore, in this case, direct assay of LDL cholesterol levels can 
be used. In addition, direct assay of LDL cholesterol should also be 
used in subjects who had not fasted for at least 9 h.
A recent study, however, reported that the value of LDL cholesterol 
concentration calculated by using the Friedewald formula is 
significantly lower than the results obtained from direct assays,12) 
and this discrepancy should be accounted for in the diagnosis and 
treatment of dyslipidemia. Therefore, clinicians should ensure to use 
the same method to evaluate and longitudinally monitor the LDL 
cholesterol levels. In addition, because variabilities in the accuracy 
of test results among different manufacturers have been observed, 
this should also be accounted for when diagnosing dyslipidemia.13)
To establish the guidelines for the treatment of dyslipidemia, lipid 
levels should be tested at least twice, at different time points. If 
there is a significant difference between the results from the first 
and second tests, then a third test should be conducted to decide 
the treatment goals according to the finally verified lipid level.11) 
The criteria for the diagnosis of dyslipidemia according to 
KNHANES are shown in Table 2-1.



















LDL: low density lipoprotein, HDL: high density lipoprotein. *The LDL cholesterol “High” criterion for diagnosis can be used as the recommended criterion to start 
medication in the low-risk group of patients (with one or few major cardiovascular risk factors). For patients with intermediate risk, the LDL cholesterol “Border-
line high” criterion can be used as the recommended criterion to start medication. For patients at a high risk, the LDL cholesterol “Normal” criterion can be used 
as the recommended criterion to start medication. For the very high-risk group, medication is recommended to be started regardless of the LDL cholesterol level
LDL cholesterol=Total cholesterol–HDL cholesterol–Triglyceride/5
(unit of concentration for each item: mg/dL)
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The US NCEP criteria for lipid and lipoprotein levels can be used 
to evaluate the performance of a clinical laboratory for testing of 




The ACC/AHA guidelines on the treatment of blood cholesterol 
were published in 2013, after the revised ATP III guidelines were 
announced in 2004.4) Without the criteria for LDL cholesterol goal, 
the 2013 ACC/AHA guidelines recommended to administer high-
intensity statins (expected to lower LDL cholesterol concentration 
by ≥50%) or moderate-intensity statins (expected to lower LDL 
cholesterol concentration by about 30-50%), depending on the 
risk levels. However, the degree of decrement in lipid levels per 
administration intensity greatly varies among patients, and thus, 
administering moderate- or high-intensity statins to all patients 
without certain therapeutic goals does not seem to be supported 
by sufficient evidence. Considering the fact that the results from 
Asian studies were not included in the establishment of the 2013 
ACC/AHA guidelines, a study on the benefits and adverse effects 
of high-intensity administration in Asia, including Korea, is 
necessary. In addition, the 2013 ACC/AHA guidelines recommend 
Table 2-2. Recommendations for treatment per risk level and LDL cholesterol concentration
Risk level
LDL cholesterol (mg/dL)
70-99 100-129 130-159 160-189 ≥190
Very high risk* 



















and consider drug if 
uncontrolled 
Lifestyle modification 
and drug intervention 
Lifestyle modification 






Two or more major risk 
factors
Lifestyle modification 
and consider drug if 
uncontrolled
Lifestyle modification 









One or few major risk 
factors
Lifestyle modification 
and consider drug if 
uncontrolled
Lifestyle modification 
and consider drug if 
uncontrolled
Lifestyle modification 






* Upon the onset of acute myocardial infarction, administer statin regardless LDL cholesterol concentration. at baseline. For very high risk cases other than 
AMI, statin administration can be considered even at <70 mg/dL of LDL cholesterol. †If carotid artery stenosis >50% is verified. ‡For intermediate and low 
risk cases, consider to start statin if LDL cholesterol concentration is high even after lifestyle modification for weeks or months. LDL: low density lipoprotein
Table 2-3. LDL cholesterol and non-HDL cholesterol goals in different risk categories
Risk level LDL cholesterol goal (mg/dL) Non-HDL cholesterol goal (mg/dL)
Very high risk 
Coronary artery disease 
Ischemic stroke 









Two or more major risk factors
<130 <160
Low risk
One or few major risk factors
<160 <190
*If carotid artery stenosis >50% is verified. LDL: low density lipoprotein, HDL: high density lipoprotein
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the administration of statins for primary prevention in patients 
with a 10-year risk of atherosclerotic CVD (ASCVD) of ≥7.5%. 
However, this recommendation has been reported to overestimate 
the risk of ASCVD in Europeans and Asians,15)16) thereby making 
it not generally applicable to Asians. This has aroused the need 
for the establishment of new criteria generally applicable to the 
Korean population. However, owing to the insufficient data on 
cardiovascular risk from large-scale Korean cohort studies, the 
criteria should be established on the basis of currently existing 
Korean and international guidelines, and further be validated.
2) New Korean criteria for treatment
New Korean treatment guidelines, as in the previous Korean 
guidelines of treatment, determines the presence of cardiovascular 
risk factors and maintains the same structure, in which the goal 
of LDL cholesterol concentration is graded according to the risk 
level. However, they were further modified and revised according 
to Korean and foreign research results, as well as 2013 ACC/AHA 
guidelines (Tables 2-2, 2-3, and 2-4).
(1) Very high risk
Patients with CVD (CAD, ischemic stroke, transient ischemic 
attack [TIA], or PAD) are classified as very high risk, and targeting 
LDL cholesterol <70 mg/dL or reducing ≥50% of the baseline value 
is indicated for secondary prevention (class of recommendation I, 
level of evidence A). 
This recommendation is based on the results from multiple 
studies with subjects with a recent history of angina,17) ischemic 
stroke, TIA,18) and peripheral vascular diseases,19) in which the 
maximal preventive effect against CVD was seen when the level of 
LDL cholesterol was lowered to <70 mg/dL or <50% of the baseline 
levels with statin therapy. However, there is a need to conduct a 
nationwide study in the future, in order to establish the Korean-
specific goal of LDL cholesterol levels. In consideration of previous 
Korean and global research results,20)21) immediate statin therapy is 
recommended to be started in patients with AMI, regardless of the 
baseline LDL cholesterol concentration (I, A).
(2) High risk
Although classified as high risk in the previous guideline, patients 
with a history of CVD are separately classified as very high risk in the 
revised version of the guideline. Meanwhile, patients with carotid 
artery disease (carotid artery stenosis >50%), abdominal aneurysm, 
or diabetes, which are risk factors equivalent to CAD, are classified as 
having a high risk, as in the previous treatment guidelines. Therefore, 
treatment is recommended to be started for primary prevention if 
the LDL cholesterol level is ≥100 mg/dL (I, A). Some previous studies 
reported that carotid artery diseases result in the increased risk for 
CVD,22) whereas studies on patients without CVD but with carotid 
artery stenosis reported that the decrease in LDL cholesterol levels 
after statin therapy helped reduce major cardiovascular events and 
mortality rates.23) Likewise, the presence of an abdominal aortic 
aneurysm increases the cardiovascular mortality by approximately 
1.9%, even without accompanying CVD,24) and the administration 
of statins resulted in a significant improvement in the size of the 
aortic aneurysm and postoperative mortality in both the short 
term and the long term.25–27) In addition, administration of statins 
in subjects with type 1 and type 2 diabetes decreased the all-cause 
mortality and major cardiovascular risks.28–30) Therefore, stains may 
be required for such high-risk patients.
(3) Intermediate risk
The classification of the intermediate-risk group in the new 
guidelines follows the previous Korean treatment guidelines, in 
which moderate risk is defined as the presence of two or more 
major risk factors (Table 2-4), except for the LDL cholesterol 
Table 2-4. Major risk factors (LDL cholesterol excluded)*
Smoking status 
Hypertension
Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg 
or taking antihypertensive agents
Low HDL cholesterol (<40 mg/dL)
Age
Male ≥45 years old 
Female ≥55 years old
Family history of premature coronary artery disease
If any of the parents or siblings (male: <55 years old, female: < 65 years old) has CAD
*High HDL cholesterol (≥60 mg/dL) is considered as a protective factor, and one factor is excluded from the total the number risk factors. LDL: low density 
lipoprotein, HDL: high density lipoprotein, CAD: coronary artery disease
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criteria. Likewise, starting statin therapy should be considered 
in patients with LDL cholesterol levels ≥130 mg/dL even after 
appropriate lifestyle modification for weeks and months (II, B). 
Each component constituting major risk factors is established 
according to the preexisting ATP-III guidelines and current Korean 
guidelines. Previous studies showed that a nonsmoking status, 
hypertension, low HDL cholesterol, and a family history of CVDs 
are associated with increased incidence of CVD.31-34) Moreover, it 
was reported that increasing age leads to increased cardiovascular 
risk; however, females show similar risks of CVD to those of males 
after 10–15 years.35) However, it was reported that such major risk 
factors can predict only half of the actual risk of CVD.11) Therefore, 
other risk factors such as obesity, physical activity, dietary habits, 
triglycerides, high-sensitivity C-reactive protein, lipoprotein (a), 
apolipoprotein, fibrinogen, homocysteine, apolipoprotein B, ankle-
brachial blood pressure index, carotid intima-media thickness 
(clinically suspected progression even with <50% stenosis or the 
presence of atherosclerotic plaques), and coronary calcium score 
should be considered to establish an individualized therapeutic goal.11)
(4) Low risk
Patients with one or few major risk factors (Table 2-4), except 
for LDL cholesterol, are classified in the low-risk category. For this 
group, it is reasonable to start statins, as in the previous treatment 
guidelines, if the LDL cholesterol concentration is ≥160 mg/dL even 
after modifying lifestyle for weeks or months (II, B).
Although the revised guidelines defined the LDL cholesterol goal as 
<160 mg/dL as in the previous treatment guidelines, a more intensified 
treatment goal also is reasonable for low-risk patients depending on 
the case, as other risk factors can be considered other than the major 
risk factors in the intermediate-risk group, as mentioned above (II, B).11)
In particular, if LDL cholesterol is ≥190 mg/dL, it is necessary to 
check if there are other causes of dyslipidemia (biliary obstruction, 
nephrotic syndrome, hypothyroidism, pregnancy, and history of 
taking medicines such as glucocorticoid and cyclosporine) before 
any treatment.4) If LDL cholesterol is found to be ≥190 mg/dL without 
any secondary causes, starting statin therapy is recommended 
regardless of risk levels, which also complies with the 2004 ATP III 
revision9) and the 2013 ACC/AHA treatment guidelines (I, A).4)
(5) Guidelines of treatment for hypertriglyceridemia 
For the treatment guidelines for hypertriglyceridemia, if the 
blood triglyceride concentration is elevated to ≥500 mg/dL, it is 
recommended to determine if there is any secondary cause: weight 
gain, drinking, carbohydrate intake, chronic renal failure, diabetes, 
hypothyroidism, pregnancy, estrogen therapy, history of taking 
medicines such as tamoxifen or glucocorticoid, and/or genetic issues 
(I, A).4) In addition, if the blood triglyceride concentration is elevated 
to ≥500 mg/dL, it is known that there is a risk of acute pancreatitis.36) 
Therefore, if the triglyceride concentration is continuously found 
to be ≥500 mg/dL even after the above-mentioned causes have 
been corrected, starting medication with fibrate, nicotinic acid, or 
omega-3 fatty acid should be considered (II, A), which also complies 
with the ATP III11) and the ESC/EAS guidelines.3)
If the triglyceride concentration is between 200 and 500 mg/dL, it 
is recommended to prescribe statin therapy, as the first treatment, 
according to the calculated cardiovascular risk level (I, A).
As the secondary goal, adjusting the non-HDL cholesterol level 
may be considered. As previously mentioned, the treatment goal 
should be adjusted according to the criteria in Table 2-3, by calculating 
the non-HDL cholesterol concentration (=Total cholesterol−HDL 
cholesterol) (II, B). The target concentration of non-HDL cholesterol 
can be acquired by adding 30 to the existing LDL cholesterol target. 
When the triglyceride (TG) level is ≥200 mg/dL in a patient with 
hypertriglyceridemia even after lifestyle modifications and statin 
therapy, it is reasonable to prescribe triglyceride lowering agents 
(e.g., fibrate, nicotinic acid and omega-3 fatty acid) in addition to 
statins for those patients that belong to a very high-risk or high-
risk group in order to prevent CVD (II, B); however, there is a need 
for a future study on the usefulness of such combination therapy 
because it is still a controversial issue.37)
3) Conclusion
In conclusion, although there would be many issues in applying 
the 2013 ACC/AHA guidelines to Koreans, the goal of the revised 
treatment guidelines is to prevent delays in the treatment by 
separating the very high-risk patient group and stratifying the 
criteria, in consideration of the fact that statin should be started 
immediately for those with CVDs or with the equivalent risk factors. 
Still, there will be a need for an additional study on the domestic 
population, with respect to the statin dosage and LDL cholesterol 
goal appropriate to Korea as well as hypertriglyceridemia control 
goal for primary prevention. 
4) Summary
Recommendations





The primary goal is to reduce LDL cholesterol 
concentrations to <70 mg/dL or ≥50% of the 
baseline value for secondary prevention, by 
classifying patients with CVD (CAD, ischemic 
stroke, TIA, peripheral vascular diseases) as 
the very high-risk group.
I A
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Continued
Statins should be immediately prescribed 
regardless of the baseline LDL cholesterol 
concentration in patients with AMI.
I A
Patients with carotid artery disease (carotid  
artery stenosis >50%), abdominal aneurysm, 
or diabetes belong to the high-risk group, 
and treatment is indicated to be started for 
primary prevention, if the LDL cholesterol is 
≥100 mg/dL.
I A
Patients with two or more major risk factors 
except for LDL cholesterol are classified as 
the intermediate-risk group. Statins should 
be considered if the LDL cholesterol concen-
tration is ≥130 mg/dL even after lifestyle 
modification for weeks or months.
II B
Patients with one or few major risk factors 
except for LDL cholesterol are classified as the 
low-risk group. Statins should be considered 
if the LDL cholesterol concentration is ≥160 
mg/dL even after improving life habits for 
weeks or months.
II B
If LDL cholesterol is ≥190 mg/dL, it should be 
checked if there is any other reason causing  
dyslipidemia (biliary obstruction, nephrotic syn-
drome, hypothyroidism, pregnancy, and history 
of medicines such as glucocorticoid or cyclo-
sporine) before any correction. These causes of 
secondary dyslipidemia should be treated.
I B
If the LDL cholesterol is ≥190 mg/dL without 
any secondary causes, statins is recommended 
to be prescribed regardless of the risk levels.
I A
If the blood triglyceride concentration is elevat-
ed to ≥500 mg/dL, it is recommended to check 
whether there is any secondary reason for the 
hypertriglyceridemia (weight gain, alcohol 
drinking, carbohydrate intake, chronic renal 
failure, diabetes, hypothyroidism, pregnancy, 
estrogen therapy, and history of taking 
medicines such as tamoxifen or glucocorticoid) 
and whether there is any genetic problem that 
could cause the lipid metabolism condition.
I A
If the triglyceride concentration is continuously 
≥500 mg/dL, medications such as fibrate, 
nicotinic acid, and omega-3 fatty acids should 
be considered to prevent pancreatitis.
II A
If the triglyceride concentration is between 
200 and 500 mg/dL and the LDL cholesterol is  
elevated simultaneously, statins is recom-
mended to be prescribed first in order to lower 
the LDL cholesterol to the target level.
I A
For very high-risk and high-risk patients, when 
the triglyceride level is ≥200 mg/dL even after 
lifestyle modification and statin therapy, 
additionally administering medicine that lowers 
triglycerides, including fibrate, nicotinic acid, 
and omega-3 fatty acid, should be considered 
in order to prevent cardiovascular diseases.
II B 
3. Monitoring of lipids and enzymes 
In the revised guidelines, the recommendation levels consider 
both the existing domestic guidelines and the global guidelines.3)4) 
It is recommended to evaluate the response to treatment and the 
patient compliance by conducting the lipid test before treatment, 
and to repeat the same test again in 6–12 weeks after starting 
medication, and then at intervals of 3–12 months depending on 
the degree of lipid lowering and the patient’s cardiovascular risk 
level (I, A).
Liver function test should be conducted before the initiation of 
statin therapy, and then the follow-up test should be conducted 
together with the lipid test after statin therapy. It is indicated that 
statin should be discontinued when the hepatic enzyme levels 
are elevated to ≥3 times the normal levels (I, A). In addition, if a 
patient complains of muscular pain and weakness, and if creatine 
kinase (CK) is ≥10 times the normal level after taking statins, it is 
reasonable to stop the administration owing to the diagnosis of 
myopathy (II, A). 
In addition, as previous studies reported slight elevation of blood 
creatinine after fibrate therapy, the domestic guidelines also suggest 
checking the creatinine level before and after 1–3 months of fibrate 
therapy. If there is no further abnormal findings afterwards, it is 








Lipid measurement should be made before 
starting statins and at 6–12 weeks after  
therapy to evaluate the response to therapy 
and adherence. Thereafter, lipid measure-
ment is  
recommended with an interval of 3–12 
months depending on the extent of lipid 
lowering.
I A
Testing of liver function is indicated before 
and after statin therapy. Discontinuation of 
statin is recommended when hepatic enzyme 
levels increase ≥3 times.
I B
Discontinuation of statin should be consid-
ered when the CK level increases ≥10 times 
in patients with myopathy symptoms after 
statin therapy.
II A
It is reasonable to check blood creatinine 
before and at 1–3 months after fibrate 
therapy, and then to observe it on a regular 
basis, if there are no adverse effects.
II B
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Chapter 3. Lifestyle Modifications for Dyslipidemia
In the prevention and treatment of dyslipidemia, lifestyle 
modifications are very important. To lower the risk levels of 
dyslipidemia, cessation of smoking is very important, whereas 
improvement of eating and exercise habits is also important in order 
to reduce the risk levels of dyslipidemia and for treatment purposes.
1. Diet 
1) Energy
Obesity and weight gain are associated with the onset of 
dyslipidemia. Many studies with obese or overweight subjects have 
reported that the levels of total cholesterol, LDL cholesterol, and 
triglycerides in blood decreased after weight reduction.38) Therefore, 
maintaining weight at the approximate level requires controlling the 
energy intake.3)4) Generally, a body mass index (BMI) of ≥30 kg/m2 
is classified as obesity. However, there is an opinion in Korea that 
any BMI ≥25 kg/m2 should be classified as obesity. Patients with 
obesity can improve their cholesterol and triglyceride levels by 
losing weight by about 5–10%, despite failing to achieve a normal 
body weight. It is generally known that a low-calorie diet with an 
energy intake reduced by about 500 kcal than normal causes no 
special harm to a person’s health and is easy to follow.
2) Fat
It has been traditionally recommended to limit fat intake for 
dyslipidemia treatment. Indeed, some reports showed that reduced 
fat intake improves blood LDL cholesterol level; however, in most 
cases these are compound reduction effects of losing weight, both 
for reduced saturated fat and trans fat intake. In addition, it is difficult 
to determine the effect of reducing the total fat intake. Moreover, fat 
limitation relatively increases carbohydrate intake, and it is found that 
increasing carbohydrate intake elevates the blood triglyceride level.39) 
However, a high fat intake may have a negative impact on blood lipid 
levels by increasing the intake of saturated fat and energy, and thus 
fat intake should be maintained at an appropriate level.
The ESC/EAS guidelines recommended not to increase fat intake 
in excess of 35% of the total calories.3) The fat intake in Koreans is 
about 20% of the total calorie intake. The Dietary Reference Intake 
for Koreans recommends that the appropriate fat intake should 
be 15–25% of the total calories. Fat intake in Korea is lower than 
that in Western countries40); however, there is a wide variation 
depending on each person, with increasing fat intake in recent 
years. It is well known that the types of lipid have more impact on 
blood lipid levels rather than the amount of total fat intake, and it is 
necessary to ensure that fat intake does not exceed 30%.
Rather than limiting the amount of total fat intake, the influence 
of the type of fatty acids on the blood lipid levels should be taken 
into account. It was found that if saturated fatty acids were 
replaced with unsaturated fatty acids, the level of blood LDL 
cholesterol can be lowered, and that there is a positive influence 
on the levels of blood triglycerides and HDL cholesterol if trans 
fatty acids were replaced with unsaturated fat.41) Therefore, for 
the treatment of dyslipidemia, there is a need to limit the intake of 
saturated fatty acids and trans fatty acids. The ATP III and ESC/EAS 
guidelines recommend limiting the intake of saturated fatty acids 
to <7% of the total energy,3)11) whereas the ATP III and 2013 ACC/
AHA guidelines recommend minimizing the intake of trans fatty 
acids.4)11) Saturated fatty acids are mainly found in meat fat, poultry 
skin, butter, and palm oil. The major sources of trans-fatty acids 
are hydrogenated oil, including margarine and shortening, and high 
amounts of trans fatty acids are also contained in oils treated for a 
long time at a high temperature.
Omega-3 fatty acids have no positive effect on blood cholesterol 
levels; however, hypertriglyceridemia can be lowered if 2–4 g is 
taken daily.42)
Replacement of saturated fatty acids with polyunsaturated fatty 
acids is effective in improving the blood cholesterol and triglyceride 
levels; however, it is recommended to take <10% of the total energy 
in order to prevent lipid peroxidation of plasma lipoprotein.
Cholesterol intake has less influence on the blood LDL cholesterol 
level, and there are wide individual variations in both saturated fat and 
trans fat. However, it is desirable to avoid excessive cholesterol intake. 
The ESC/EAS guidelines recommend an intake of <300 mg daily.3)
3) Carbohydrate
Excessive carbohydrate intake, especially excessive 
monosaccharide intake, increases the blood triglyceride level. 
Soluble dietary fiber is effective in improving blood cholesterol 
and triglyceride levels.43) Therefore, it is recommended to reduce 
monosaccharide intake and to consume mixed grains, marine algae, 
and vegetables that contain large amounts of soluble dietary fiber.
ATP III recommends 10–25 g of soluble dietary fiber daily, whereas 
the ESC/EAS guidelines recommend 5–15 g of soluble dietary fiber 
daily (25–40 g of the total dietary fiber).11)
Sufficient amount of food rich in dietary fiber should be taken so 
as to reach a fiber intake of ≥25 g.
4) Alcohol
Excessive alcohol intake (≥10–30 g/day) should be avoided because 
it affects the blood triglyceride level.44) Hypertriglyceridemia caused 
by alcohol intake is associated with decreased activity of lipoprotein 
lipase, which results in the inhibition of chylomicron catabolism. The 
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ESC/EAS guidelines recommend that alcohol consumption should be 
limited to 1–2 glasses/day (males: <20–30 g, females: <10–20 g), and 
even to stop drinking especially in patients with hypertriglyceridemia.3) 
5) Dietary pattern 
More recently, there are many studies being conducted not on the 
respective nutrients but on the relations between diet pattern and 
diseases. Eating habits are classified according to the types food or 
their combination. In Western countries, there are studies currently 
being conducted on the effects of eating habits such as the Dietary 
Approaches to Stop Hypertension (DASH) diet and the Mediterranean 
diet on blood lipid levels. On the basis of such studies, the 2013 ACC/
AHA guidelines recommend applying diet plans such as the DASH 
diet, US Department of Agriculture food pattern, and AHA diet.4) 
In Korea, there are only a few studies on the relationship between 
dyslipidemia and eating habits. However, it will be helpful to have 
a diet that includes a higher portion of whole grains such as mixed 
grains, brown rice, and whole wheat, with foods such as vegetable, 
beans, fish, fruit, and dairy products.45) On the basis of many previous 
studies, it is helpful to sufficiently consume fruit and vegetables, 
in order to prevent and treat dyslipidemia. However, carbohydrate 
accounts for a relatively higher portion of the Korean diet with fruit 
consumed as dessert and eating between meals rather than as a 
regular diet. Extra care should be paid because extra consumption of 
fruit may increase the monosaccharide intake. The ESC/EAS guidelines 
recommend taking about 200 g of fruits daily.3) Table 3-1 shows how 
to select foods appropriately.
< Examples of rough estimates per fruit type, equivalent to 200 g >
1 small apple, 2 tangerines, 1 orange, 1 small oriental melon, 
1 tomato, 2 kiwis, or 1 persimmon
*1.  Please use this only as reference because the actual size of the 
fruit may vary according to the subjective point of view. 








Energy intake should be limited to the 
amount of energy needed to maintain a 
healthy weight.
I A
Total fat intake should be limited not to  
exceed 30% of the calorie intake amount.
I A




however, be careful not to eat an excessive 
amount





- Fat-removed meat 
- Poultry without skin
- Seasoned meat, ribs, intestines
- Poultry skin, fried chicken
- High-fat processed meat (spam, sausage, bacon, etc.)
- Fish eggs, intestines
Eggs - Egg white - Egg yolk, quail egg, duck egg yolk
Dairy products
-  Skimmed milk, nonfat dry milk, low fat (fat-free)  
 milk and related products
- Low fat cheese
- Whole milk, condensed milk and related products




-  Unsaturated fatty acid: sunflower oil, corn oil,  
 soybean oil, perilla oil, olive oil
- Low fat/fat-free salad dressing
- Nuts: peanuts, walnuts, etc.
- Coconut oil, palm oil
- Butter, lard, shortening, bacon oil, beef tallow 
- Yolk, cheese, salad dressing made of whole milk
- Solid margarine
Grains - Mixed grains, whole wheat
-  Bread, cake mainly made of egg and butter, high fat cracker, 
 biscuit, chip, butter popcorn, etc.
- Pie, cake, doughnut, high fat snacks
Soup - Soup with fat removed after cooking - Greasy soup, cream soup
Vegetables/
fruits
- Fresh vegetable, marine algae, fruit
- Vegetables/fruits fried or added with butter, cheese, cream or sauce




- Products with coconut oil and palm oil
- Fried snacks
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Continued
Saturated fatty acid intake should be limited 
to <7% of the calorie intake.
I A
Replacement of saturated fatty acid with  
unsaturated fatty acid should be considered, but 
the N6-polyunsaturated fatty acid intake amount 
should be limited within 10% of the total calorie.
II B
Trans-fatty acid intake should be avoided. I A
Cholesterol intake should be limited <300 
mg daily.
I B
Carbohydrate intake should not be excessive, 
and monosaccharide intake should be reduced.
I B
Foods rich in dietary fiber should be con-
sumed sufficiently, so that dietary fiber 
intake may be ≥25 g.
I A
Alcohol intake should be limited to within 
1-2 glasses daily.
I A
It is reasonable to intake foods such as 
whole grains and mixed grains, beans, 
vegetables, and fish:
-  Whole grains and mixed grains as part of a  
 main meal;
-  Sufficient amounts of many kinds of  
 vegetables;
-  Fish intake (in particular, lean and oily fish  
 about 2–3 times a week;
- Moderate amount of fruits (≤200 g/day).
II B
2. Exercise 
1) Exercise and its effects on lipid metabolism
Whether or not regular exercise leads to any changes in blood 
lipid levels is controversial because various results have been 
reported depending not only on the subjects’ sex, age, race, 
and lipid concentration but also on the type, amount, intensity, 
duration, and frequency of exercise, as well as on whether lifestyle 
and body weight changed with regular exercise habits.46) Moreover, 
regular exercise does not have a great impact on lipid levels. 
Exercise is classified as either aerobic exercise or anaerobic exercise. 
It was reported that there are some differences in the change of 
cholesterol level according to exercise types.
Aerobic exercises increase physical oxygen consumption; these 
exercises include walking at a rapid pace, jogging, swimming, and 
bicycling that can be maintained for ≥30 min, enhancing cardiovascular 
endurance. Meanwhile, anaerobic exercises include short-distance 
running, push-ups, throwing, and jumping within 10 s, which are good 
for strengthening muscles by using instant power.
In general, aerobic exercises help reduce triglycerides and increase 
HDL cholesterol level, with minor changes in LDL cholesterol.47)48) Exercise 
therapy undoubtedly prevents CVD; however, such effects are not very 
clearly observed. The goal of controlling lipid metabolism is to prevent 
CVD, and exercise therapy is important for a patient with dyslipidemia.46)49) 
The effects of anaerobic exercises on lipids is more controversial.50)51) 
For other CVDs, their effect of controlling risk factors are lower than 
those of aerobic exercises. However, anaerobic exercises increase 
muscle mass and muscle strength, increasing physical activities 
and improving daily performance especially for older persons.46)
Healthy adults may start aerobic exercises with moderate or 
less intensity, whereas elderly persons or those with multiple risk 
factors or CVD need medical consultation before starting exercise, 
and are subjected to a cardiovascular stress test by using a treadmill 
or a bicycle, if needed.46) Medical assessment is required before a 
patient starts performing anaerobic exercises. Therefore, not only 
exercises but also increasing physical activities are recommended 
because these are both associated with the prevention of CVD.52)
2) Exercise prescription
There are no special exercise prescriptions for controlling dyslipidemia; 
however, the same methods are used to prevent CVD.46)53) 
The types of recommended aerobic exercises include walking 
at a quick pace, jogging, swimming, or bicycling. The appropriate 
frequency is 4–6 days/week, whereas the intensity is 55–75% of 
Table 3-2. Summary of exercise therapy for dyslipidemia patients
Type & order Intensity Duration Frequency Considerations
Warm-up: 








Stretching after light walking 
55-75% of the 
maximum heart rate








4-6 days weekly When setting the intensity, the calculation 
method for the expected maximum heart 
rate is not applicable to a patient who 
takes a β-blocker or nondihydropyridine 
calcium-channel blockers
RPE: rating of perceived exertion
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the maximum heart rate (=220–age). However, the target heart 
rate should not be applied to a patient with CVD who is taking a 
β-blocker or nondihydropyridine calcium-channel blockers. When 
the intensity of the exercise starts to feel “moderate,” it is good to 
intensify the exercise and maintain it at the level of “a little tough”. 
Warm-ups should start with light stretching and walking for 
5–10 min, followed by 30–60 min of aerobic exercises as the main 
workout. It is possible not only to do continuous exercises but 
also to do them in 10-min sets. Then, complete it with some light 
walking and stretching for 5–10 min. Table 3-2 summarizes the 








Moderate-intensity aerobic exercises should 
be performed on a regular basis
I A
Physical activities should be increased. I A
It is reasonable to do anaerobic exercises on 
a regular basis.
II B
If patients have multiple risk factors or CVD, 
medical consultation is recommended before 
doing exercises.
I A
Chapter 4. Pharmacological Therapy for Dyslipidemia
1. Selection of drugs
It is important to combine lifestyle modification together with 
medication. Lifestyle modification includes diet therapy, exercise 
therapy, or abstaining from smoking. To determine whether to start 
drug therapy, a comprehensive consideration should be given to 
both the risk level of CVD and the LDL cholesterol levels. The risk 
level for CVD should be classified as one of the following: low, 
intermediate, high, or very high. 
The treatment with drugs can be initiated according to 
whether the patients have CAD, PAD, ischemic cerebral infarction, 
atherosclerotic artery disease (aortic aneurysm, TIA, severe carotid 
artery stenosis), or diabetes, as well as on the number of CAD risk 
factors (smoking, hypertension, low HDL cholesterol level, family 
history of premature CAD, and age).
Statin is the first-choice drug for the treatment of 
hypercholesterolemia. The dosage is recommended to be adjusted to 
reach the target LDL cholesterol level according to the cardiovascular 
risk level (class of recommendation I, level of evidence A).3)4)
The first goal for drug therapy is to lower the LDL cholesterol 
to the target level or below (I, A), whereas the secondary goal is 
to lower the non-HDL cholesterol to target level or below (IIa, B).11)
Secondary causes of hypercholesterolemia should be considered 
and corrected before starting any medication (Table 4-1).
1) Low density lipoprotein cholesterol 
Very high-risk group: This group includes patients with CAD, 
PAD, and/or ischemic stroke. The goal is to reduce LDL cholesterol 
concentration to <70 mg/dL or to reduce it by ≥50% than the baseline 
value (I, A). Statin treatment can be considered regardless of the 
baseline LDL cholesterol level.3)4) There are some reports on additional 
beneficial effects on clinical prognosis for patients with acute coronary 
syndrome (ACS), when LDL cholesterol is lowered down to 54 mg/dL.
For patients with AMI, statins is indicated to be administered 
immediately regardless of the baseline LDL cholesterol concentration 
(I, A).20)21)
High-risk group: This group includes patients with atherosclerotic 
artery disease (aortic aneurysm, TIA, or carotid artery stenosis 
>50%) or diabetes. If the LDL cholesterol is ≥100 mg/dL, statin 
medication should be started (I, A), and can be considered in 
selected patients whose LDL cholesterol level is <100 mg/dL.28-30)
Intermediate-risk group: This group includes patients with two 
or more cardiovascular risk factors (smoking, hypertension, low HDL 
cholesterol, and family history of premature CAD). Starting statin 
Table 4-1. Secondary causes of hypercholesterolemia or hypertriglyceridemia
Secondary causes High LDL cholesterol High triglyceride
Diet
Saturated fat-/trans-fat intake 
weight gain, anorexia 
Weight gain, high-carbohydrate diet, alcohol drinking
Drug
Diuretics, glucocorticoid,  
amiodarone, cyclosporine
Oral estrogen, glucocorticoid, bile acid sequestrants, protease inhibitor, retinoic acid, anabolic 
steroids, sirolimus, raloxifene, tamoxifen, β-blockers, thiazide diuretics
Disease
Obstructive liver disease, nephrotic 
syndrome
Chronic nephropathy, nephrotic syndrome
Metabolic disorder Hypothyroidism, obesity, pregnancy Uncontrolled diabetes, hypothyroidism, obesity, pregnancy
LDL: low density lipoprotein
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medication should be considered if the LDL cholesterol level is ≥130 
mg/dL (IIa, B). It can also be initiated in patients with multiple risk 
factors when their LDL cholesterol level is 100–129 mg/dL.
Low-risk group: This group includes patients with one or few 
cardiovascular risk factors (smoking, hypertension, low HDL cholesterol, 
and family history of premature CAD). If the LDL cholesterol level is 
≥160 mg/dL, statin medication should be considered (IIa, B).
2) Triglycerides 
If the triglyceride concentration is high, it is recommended 
to first determine whether there are other factors increasing 
triglycerides and then to establish the treatment plan by evaluating 
the cardiovascular risk level (Table 4-1).
As about 10% of acute pancreatitis is known to be caused by 
hypertriglyceridemia, it is important to modify lifestyle and medication 
should be started immediately to prevention acute pancreatitis, 
when the triglyceride concentration is ≥500 mg/dL (I, A). Lifestyle 
modification with a low-fat diet (reduced to 10–15% of the caloric 
intake) and cessation of drinking are required. Combined with lifestyle 
modification, medication should be started first by using fibric acid 
derivatives (I, B), nicotinic acid (IIa, B), or omega-3 fatty acids (IIa, 
B), which mainly lower triglycerides. For a diabetic patient, it will be 
helpful to strictly control blood glucose by using insulin, whereas 
apheresis can be helpful if there is a need to achieve rapid reduction.54)
When the triglyceride level is between 200 and 499 mg/dL, the 
first treatment goal is to lower the LDL cholesterol to the target level 
based on the calculated cardiovascular risk level (I, A). Therapeutic 
lifestyle modification and statin medication can be considered to 
achieve the goal. After achieving the LDL cholesterol goal, when 
triglycerides are still ≥200 mg/dL, it is reasonable to use triglyceride-
lowering agents especially for the high-risk and very high-risk 
groups (IIa, B). Fibric acid derivatives (I, B), nicotinic acid (IIa, B), and 
omega-3 fatty acids (IIa, B) are used to control triglycerides.55–57) 
When the triglyceride level fails to reach the target level with a 









The first goal is LDL cholesterol for  
dyslipidemia treatment. 
I A
As the secondary goal after the control of 
LDL cholesterol target level, non-HDL  









Statin should be prescribed and the dose  
adjusted to reach the LDL cholesterol target 
level in high-risk and very high-risk groups 
according to the criteria for treatment.
I A
For the low-risk or intermediate-risk groups, 
statin use should be considered if LDL choles-
terol is not reduced to the first target even after 
lifestyle modification for weeks or months.
IIa B
In case of statin intolerance, bile acid seques-
trants or nicotinic acid should be considered.
IIa B
If the target level of LDL cholesterol is not 
reached with statin, combination treatment 
with ezetimibe should be considered.
IIa B
If the target level of LDL cholesterol is not 
reached with statin, combination treatment 
with nicotinic acid and bile acid sequestrants 
may be considered.
IIb C
In the very high-risk group, if the first target 
is not reached even with single statin use or 
combination therapy, it is recommended to 
reduce the LDL cholesterol level to ≥50% 
compared with the baseline level.
I A
For AMI, statin should be immediately prescribed 









When the triglyceride level is ≥500 mg/dL, it is 
important to modify lifestyle and to start 
medication that immediately lowers triglycer-
ides in order to prevention acute pancreatitis.
I A
When the triglyceride level is between 200 and 
499 mg/dL, the first treatment goal is to lower 
the LDL cholesterol to the first target based on 
the calculated cardiovascular risk level.
I A
When the triglyceride level is between 200 
and 499 mg/dL, the secondary goal is to 
control non-HDL cholesterol to less than the 
target, if the triglyceride level is ≥200 mg/dL 
after achieving the LDL cholesterol goal.
IIa B
When the triglyceride level is between 200 
and 499 mg/dL, triglyceride-lowering agents 
should be considered after achieving the LDL 
cholesterol goal, if the triglyceride level is 
≥200 mg/dL with cardiovascular risk factors, 
or if the non-HDL cholesterol is over the 
target.
IIa B
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If indicated, fibric acid derivative should be 
used as drug to control triglycerides.
I B
If indicated, nicotinic acid should be  
considered as drug to control triglycerides.
IIa B
If indicated, it is reasonable to use omega-3 
fatty acid as a drug to control triglycerides.
IIa B
If the triglyceride level fails to reach the first 
target with single-drug therapy, combination 
therapy should be considered.
IIa C








The first treatment goal is to control LDL 
cholesterol to target level or less.
I A
To raise HDL cholesterol, nicotinic acid 
should be considered. 
IIa A
To raise HDL cholesterol, fibric acid may be 
considered.
IIb B
2. Characteristics of lipid-lowering agents
1) Statins: 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors 
Statins are first recommended for the treatment of dyslipidemia 
among currently available drugs because it has a relatively low 
risk profile and proven effects of decreasing CVD by lowering LDL 
cholesterol.58)
(1) Action mechanism
All types of statins reduce cholesterol synthesis by competitively 
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, 
which is a cholesterol precursor.59) In hypercholesterolemia, to 
maintain homeostasis in the cellular level, the expression of LDL 
receptors should increase and the synthesis of cholesteryl ester 
should decrease.
As a result, more blood LDL cholesterol is removed and production 
of VLDL cholesterol decreases in the liver, resulting in the decrease 
of LDL cholesterol. Statins not only block such synthesis but also 
inhibit the synthesis of lipid intermediates, which have important 
biological effects. Metabolites such as geranylgeranyl pyrophosphate 
and farnesyl pyrophosphate prenylate proteins. Through this process, 
the molecules are attached to the cell membrane, enhancing their 
biological activities. The geranylgeranylation of Rho A and the 
inhibition of phosphorylation of peroxisome proliferator-activated 
receptor alpha, which regulates the transcription of apo A1, are 
considered as the mechanisms of how statin raises the HDL cholesterol 
level. Alteration of protein prenylation seems to mediate some effects 
of statins other than their LDL cholesterol-lowering effect. 
(2) Types of statin 
The currently available statins include lovastatin, pravastatin, 
simvastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin.
(3) Effects on lipid level
Each statin is different in terms of absorption, blood protein 
binding, excretion, and solubility, with variable LDL cholesterol-
lowering effects per dosage (Table 4-2).60–63) When the statin 
Table 4-2. Lipid-lowering efficacy of the currently available statins
Lovastatin Pravastatin Simvastatin Fluvastatin Atorvastatin Rosuvastatin Pitavastatin
Daily dosage (mg) 20-40 10-40* 20-40 20-80 10-80 5-20† 1-4





























*Daily dosage in foreign countries: 40-80 mg, †daily dosage in foreign countries: 5-40 mg. LDL-C: low density lipoprotein cholesterol, TG: triglyceride, 
HDL-C: high density lipoprotein cholesterol
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dosage is doubled, the LDL cholesterol level additionally decreases 
by 6% in general. In addition, when statins are used in patients 
with hypertriglyceridemia, the triglyceride level also decreases by 
22–45% because the VLDL cholesterol secretion in the liver is 
inhibited. HDL cholesterol slightly decreases by 5–10%. Many studies 
on Koreans have been reported concerning the lipid-lowering effect 
of each statin. Some domestic studies reported the tendency of 
higher LDL cholesterol-lowering effects with the same dosage in 
Koreans compared with Western people (Table 4-3, Fig. 4-1).64)
(4) Cardiovascular diseases prevention research and indications
①Secondary prevention effect of cardiovascular disease: It is 
widely known that patients with CVD (angina, ACS, AMI, stroke, 
or TIA) have increasing risks of cardiovascular events or death.17–19) 
For such patients, it is recommended to use statins because these 
drugs prevent the recurrence of cardiovascular events (I, A). The 
goal for these patients, classified as the very high-risk group, is to 
reduce LDL cholesterol to <70 mg/dL or ≥50% of the baseline level 
for secondary prevention.
In case of AMI, statins are indicated to be prescribed immediately 
regardless of the baseline LDL cholesterol level (I, A).20)21)
Although there are not many large-scale studies in Asians,65) there 
is a report on better preventive outcomes in patients ≤75 years old 
with CVD when they took statins to reduce LDL cholesterol by ≥30–
50% from baseline levels. Therefore, it is reasonable to use moderate-
Table 4-3. Lipid-lowering efficacy of currently available statins in Korean
Lovastatin Pravastatin Simvastatin Atorvastatin Rosuvastatin Pitavastatin
Daily dosage (mg)





































































LDL-C: low density lipoprotein cholesterol, TG: triglycerides, HDL-C: high density lipoprotein cholesterol
Fig. 4-1. Comparison of LDL cholesterol-lowering effects by each statin 
between Koreans and Western people. LDL: low density lipoprotein.
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dose/moderate-intensity or high-dose/high-intensity statin that can 
reduce the LDL cholesterol level by ≥30–50% from the baseline levels 
(IIa, A).
For patients aged >75 years with cardiovascular diseases, it is 
reasonable to start statin after considering comorbidities and 
possible drug-drug interactions (IIa, B).66)
②Primary prevention of cardiovascular disease in the general 
population: Adults with a blood LDL cholesterol level of ≥190 mg/
dL have an increased possibility of having CVD during their lifetime. 
Therefore, statins should be prescribed if the blood LDL cholesterol 
concentration is ≥190 mg/dL even after lifestyle modification (I, A).3)4)
For an adult with a blood LDL cholesterol level of 160–190 mg/
dL, it is reasonable to use statin if the blood LDL cholesterol is ≥160 
mg/dL even after lifestyle modification for 4–8 weeks (IIa, B).
Meanwhile, for an adult with a blood LDL cholesterol of 130–160 
mg/dL, lifestyle should be properly modified, and then it may be 
decided whether to start statins in consideration of cardiovascular 
risk level (IIb, C).
③Primary prevention in patients with diabetes: For the high-
risk group, such as patients with diabetes, carotid artery disease 
(stenosis >50%), or aortic aneurysm, if the LDL cholesterol is ≥100 
mg/dL, statin should be started (I, A).28)29)
④Patients with heart failure or undergoing dialysis: For patients 
with heart failure or undergoing dialysis, statin is not indicated 
owing to the lack of evidence for a preventive effect (III, B).67–69)
(5) Dosage and administration
Lovastatin: 20-80 mg/day, recommended to be administered 
with dinner
Pravastatin: 10-40 mg/day, more effective to be administered in 
the evening
Simvastatin: 20-40 mg/day, more effective to be administered 
in the evening
Fluvastatin: 20-80 mg/day, more effective to be administered in 
the evening
Atorvastatin: 10-80 mg/day, less influenced by the time of 
medication
Rosuvastatin: 5-20 mg/day, less influenced by the time of 
medication 
Pitavastatin: 1-4 mg/day, less influenced by the time of 
medication
Pitavastatin: 1-4 mg/day, less influenced by the time of 
medication
(6) Follow-up test before/after statin medication
①Blood test before statin treatment: Before starting any statin 
treatment, the transaminase (aspartate transaminase [AST] and 
alanine transaminase [ALT]) concentrations should be measured (I, B). 
If the ALT concentration is ≥3 times than the normal range before 
medication, it is reasonable to first evaluate and treat liver diseases 
instead of immediately starting statins, and then to proceed with the 
statin medication after the liver function has normalized (IIa, C). If the 
baseline muscle enzyme (CK) is ≥3 times than the normal range, it is 
reasonable to identify the causes before starting any statin (IIa, C).
②Follow-up test after statin treatment: After the initiation of 
statin treatment, the cholesterol, triglyceride, and HDL cholesterol 
levels should be evaluated after 4–12 weeks (I, B). If LDL cholesterol 
is ≤40 mg/dL after two consecutive measurements, the statin 
dose may be reduced (IIb, C). Evaluation of liver function should 
be considered at 4–12 weeks after treatment. Thereafter, it is 
reasonable to repeat the test every 3–12 months to check the 
efficacy and hepatotoxicity of statins (IIa, C). Regular tests for 
muscle enzyme are not indicated (III, A).
(7) Adverse effect
The most common adverse effects that occur in about 4% of 
statin-treated patients include gastrointestinal disorder, heartburn, 
and stomachache; moreover, rare and fatal adverse events such as 
hepatotoxicity and muscle toxicity can also occur.58) In patients >75 
years old, as well as in patients who are taking multiple drugs or 
taking drugs with same metabolic pathway as statins, or those with 
conditions that require complex medication (e.g., heart transplant 
or AIDS), statin should be considered in low dosage (IIa, C).
①Hepatotoxicity: If there is a slight increase in transaminase, there 
is no need to stop statin. Statins should be stopped when liver enzymes 
are elevated by ≥3 times the normal range. Restarting statins may be 
considered from a low dose after the normalization of liver enzymes (IIb, 
C). If there are any symptoms suggesting liver damage, such as fatigue, 
appetite decrease, stomachache, dark-colored urine, and jaundice, 
during statin treatment, it should be considered to immediately 
perform a liver function test including AST/ALT measurement (IIa, C).
②Muscle toxicity: The most common adverse effect during 
statin medication is muscle pain. About 10% of patients taking 
statins are reported to have muscle pain and, consequently, to stop 
taking statins. Many patients discontinue statin use because of 
muscle pain or weakness. However, it is not clear whether these 
symptoms are caused by statins. The frequency of muscle damage 
due to statin is known to be higher by 0.01% in patients who are 
taking statins than that in a control group.
The elevation of muscle enzyme due to muscle damage, resulting 
in rhabdomyolysis, hemoglobinuria, and acute renal failure, is 
known to occur in only a very small portion of patients. Muscle 
damage after statin treatment occurs more often in patients with 
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multiple comorbid diseases or those with the concomitant use of 
cyclosporine, fibrate derivatives, macrolide antibiotics, or several 
antifungal drugs. Taking fibrate derivatives such as gemfibrozil with 
statin increases the risk of muscle damage, whereas fenofibrate is 
known to have a relatively low risk. The measurement of muscle 
enzyme in asymptomatic patients on a regular basis is not 
recommended (III, A). However, if there is muscle pain, weakness, or 
general fatigue, it is reasonable to measure the muscle enzymes to 
check if there is any muscle damage (IIa, C).
③Diabetes: Recently, some studies reported that statins increase 
the incidence of diabetes.70) In most cases, new-onset diabetes 
was diagnosed in persons with glucose intolerance before taking 
statins or in those who are taking high-dose statins. Therefore, 
measurement of the fasting blood glucose before taking statins 
is recommended (I, B). Even when diabetes occurs after statin use, 
it is recommended to continue taking statins in order to prevent 
CVD, in addition to lifestyle modifications such as regular exercise, 
weight control, and smoking cessation (I, B).
④Cognitive impairment: There is a report on the deterioration 
of cognitive function in patients taking statins. However, the 
adverse effects of concomitant neuropsychological drugs may be 
considered first, rather than those of statins (IIb, C).71)72)
(8) Contraindications
Statins are absolutely contraindicated for pregnant or lactating 
women and for patients with active or chronic liver disease. Statins are 
relatively contraindicated for patients taking cyclosporine, macrolide 
antibiotics, antifungal drugs, and cytochrome P-450 inhibitors.
(9) Summary
Statin: HMG-CoA reductase inhibitor 
Dosage and 
administration
Lovastatin: 20–80 mg/day, recommended to be taken 
with dinner
Pravastatin: 10–40 mg/day, more effective to be taken 
in the evening 
Simvastatin: 20–40 mg/day, more effective to be taken 
in the evening
Fluvastatin: 20–80 mg/day, more effective to be taken 
in the evening
Atorvastatin: 10–80 mg/day, less influenced by  
medication time
Rosuvastatin: 5–20 mg/day, less influenced by  
medication time
Pitavastatin: 1–4 mg/day, less influenced by medication 
time
Follow-up test
Lipid profile, liver-function test, muscle enzyme (if there 
is unexplainable muscle pain or weakness)
Adverse effect
Gastrointestinal disorder, heartburn, stomachache, 
hepatotoxicity, muscle toxicity, diabetes
Contraindica-
tions
For patients with activity or chronic liver disorder, and 
for pregnant or lactating women, statin therapy is an 
absolute contraindication. Statin therapy is relatively 
contraindicated in patients who are taking other drugs 
including cyclosporine, macrolide antibiotics, antifungal 
drugs, and cytochrome P-450 inhibitors.
2) Fibric acid derivatives
(1) Indications
Fibric acid derivatives are recommended in patients with 
hypertriglyceridemia (I, B), and reasonable to combine with statins 
in patients with mixed dyslipidemia in whom both LDL cholesterol 
and triglycerides are increased (IIa, A).73)74) In addition, there are 
a number evidences showing that fibric acid derivatives reduce 
cardiovascular risk if prescribed to patients with high triglycerides 
and with low HDL cholesterol. However, it is not recommended as 
the first-line treatment in case of only a high LDL cholesterol level.
(2) Dosage and administration
Bezafibrate: 400-600 mg/day, 1–3 times a day, after meals
Fenofibrate: 160-200 mg/day, once a day, immediately after a meal
Gemfibrozil: 600-1200 mg/day, twice a day, 30 min before meals
(3) Follow-up test before and after treatment
The baseline lipid profile, liver function, renal function, and 
muscle enzymes (if there is unexplainable muscular pain or muscle 
weakness) should be checked.3)75)
(4) Adverse effect
The most common adverse effect is gastrointestinal disorder, and 
there may be increases in the prevalence of cholesterol gallstones. 
Myopathy may occur, but with a low frequency. If renal function 
is impaired, blood drug concentration increases, with higher risks 
of adverse events. In particular, when gemfibrozil is prescribed 
together with statins, the risk of myopathy increases, whereas 
fenofibrate is preferred in combination with statins owing to the 
low risk of myopathy. Fibric acid derivatives bind with albumin, 
thereby increasing the blood level of warfarin, with subsequent 
increase in bleeding tendency; moreover, fibric acid derivatives may 
increase the effect of hypoglycemic agents. Fibric acid derivatives 
increase blood creatinine concentration but do not cause renal 
failure.
(5) Contraindications
Fibric acid derivatives are absolutely contraindicated for patients 
with severe liver disorder, gall bladder disease, hypersensitivity 
reaction to fibric acid derivatives, and renal dysfunction.






Bezafibrate: 400-600 mg/day, 1-3 times a day, after 
meals
Fenofibrate: 160-200 mg/day, once a day, immedi-
ately after a meal 
Gemfibrozil: 600-1,200 mg/day, twice a day, 30 min 
before meals (combination therapy with statin 
should be avoided)
Follow-up test
Lipid profile, liver function, blood chemistry, and 
muscle enzyme tests (when there is unexplainable 
muscular pain or muscle weakness)
Adverse effects
Gastrointestinal disorder, cholesterol gallstone, 
myopathy
Contraindications
The absolute contraindications are severe liver 
disorder, gall bladder disease, or hypersensitivity  
reaction to fibric acid derivatives. Extra caution 
should be taken in the presence of renal dysfunction.
3) Nicotinic acid (niacin)
(1) Indications
Niacin can be used for all types of dyslipidemia. For 
hypertriglyceridemia, it should be considered as the first-line 
medication (IIa, B), whereas nicotinic acid is effective for patients 
with low HDL cholesterol (IIa, A).76) For patients with high LDL 
cholesterol or mixed-type dyslipidemia, it may be considered to use 
nicotinic acid in combination with statins, if not treated with statin 
therapy alone; however, care should be taken because of the risk 
of increasing the adverse effects, including liver function disorder, 
myopathy, and increasing the incidence of diabetes (IIb, A).
(2) Dosage and administration
Regular-release nicotinic acid: Divide 1.5-3 g into three times a 
day and take with a meal or after meals
Sustained-release nicotinic acid: Not used owing to hepatotoxic 
effects
Extended-release nicotinic acid: Take 1-2 g once a day before 
going to bed
(3) Follow-up test
The baseline lipid profile, liver-function, and uric acid should be 
checked
(4) Adverse effects
Skin flushing is a common adverse effect, which can be very 
severe in some patients. Skin flushing could be reduced with long-
term continuation of medication, and the adverse effects could 
be reduced with the administration of the drug with a meal or 
by taking aspirin. Gastrointestinal disorder is frequently observed. 
Other important adverse effects include hepatotoxicity, gout, and 
elevation of blood glucose levels, in proportion with dosage and 
the duration of therapy. The risk of hepatotoxicity increases with 
sustained-release nicotinic acid, and cases of fulminant hepatic 
failure have been reported. The frequency of facial flushing is known 
to be reduced with the use of recently developed drugs.
(5) Contraindications
Nicotinic acid is absolutely contraindicated for patients with chronic 
liver disease or severe gout. Nicotinic acid is relatively contraindicated 





Regular release nicotinic acid: Divide 1.5-3 g three 
times a day and take with a meal or after meals 
Sustained-release nicotinic acid: Not used owing to 
hepatotoxic effects
Extended-release nicotinic acid: Take 1-2 g once a 
day before going to bed
Follow-up test Lipid profile, blood glucose, liver-function test, uric acid
Adverse effects
Skin flushing, gastrointestinal disorder, hepatotoxicity 
(in particular, when sustained release forms of nicotinic 
acid are used), gout, elevation of blood glucose
Contraindications
The absolute contraindications are chronic liver 
disorder or severe gout. Extra caution should be 
taken with the relative contraindications, including 
diabetes, hyperuricemia, and peptic ulcer.
4) Ezetimibe
(1) Indications
If the LDL cholesterol target level has not been reached with 
statin, ezetimibe should be considered in combination (IIa, B).68)77)
(2) Dosage and administration
Take 10 mg of the drug once. 
(3) Follow-up test
Lipid profile should be tested every 3-6 months. 
(4) Adverse effects 
The common adverse effects include stomachache, diarrhea, 
flatulence, and gastrointestinal symptoms, whereas the relatively 
uncommon adverse effects include indigestion, gastroesophageal 
reflux, appetite decrease, arthralgia, muscle spasm, and chest pain. 
Increases in transaminase, γ-glutamyltransferase, and muscle 
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enzymes have been reported.
(5) Contraindications 
This drug is not recommended if there is a hypersensitivity 
reaction (III, C). For pregnant and lactating women, it is not 
recommended to use this drug owing to safety issues (III, C). It is 
also not indicated for use in patients with acute liver disease or 





Take 10 mg of the drug once a day
Follow-up test
Blood cholesterol and triglyceride test should be  
conducted every 3-6 months.
Adverse effects
Stomachache, diarrhea, flatulence, indigestion, 
gastroesophageal reflux, appetite decrease, arthralgia, 
myospasm, chest pain, fatigue, elevations in trans-
aminase, γ-glutamyltransferase, and muscle enzyme
contraindications
Drug hypersensitivity reaction (III, C)
Pregnant and lactating women (III, C)
Patients with acute liver disease or those with 
moderate or severe chronic liver dysfunction (III, C)
5) Omega-3 fatty acids
(1) Indications
Omega-3 fatty acid alone should be considered for 
hypertriglyceridemia (IIa, B), or is reasonable to use for complex-
type hyperlipidemia in combination with statin (IIa, C).57)78)79)
(2) Dosage and administration
Take 2–4 g once or twice a day.
(3) Follow-up test
Blood lipid profile and liver-function test should be conducted at 
every 3-6 months.
(4) Adverse effects
Some of the reported adverse effects include hemorrhagic stroke, 
elevation of blood sugar levels, immunosuppressive effect, and 
dyslipidemia. Moreover, there are reports on gastrointestinal symptoms 
such as nausea, vomiting, burping, and burping with a fishy smell or taste, 
as well as on liver enzyme elevation, headache, itching, or arthralgia.
(5) Contraindications
There are no absolute contraindications for this drug, except for a 
hypersensitivity reaction. This drug belongs to pregnancy category 
C, and omega-3 fatty acids should be considered only if there are 
great benefits of using the drug (II, C). An animal study reported on 
fatal outcomes with excessive administration. There are no well-
established safety issues yet concerning use on humans during 









Blood cholesterols, triglycerides and liver-function 
test should be conducted every 3-6 months.
Adverse effect
Hemorrhagic stroke, elevation of blood sugar levels, 
immunosuppressive effect, nausea, vomiting, urping, 
burping with a fishy smell or taste, dyslipidemia due 
to increased liver somatic index, headache, itching, 
arthralgia
Contraindications Hypersensitivity reaction to the drug
Chapter 5. Dyslipidemia in Different Clinical Settings 
1. Stroke (cerebrovascular diseases)
Dyslipidemia is one of the important risk factors of CVD; 
however, there is no clear association between dyslipidemia and 
stroke in general. Although stroke considerably contributes to the 
pathological mechanism of CVD, the association with dyslipidemia 
is not clear because of the various subtypes of cerebrovascular 
disease. Many cohort studies reported that low cholesterol levels 
are associated with the incidence and mortality rate of cerebral 
hemorrhage. Therefore, a more careful approach is needed in Korea, 
where the incidence and mortality rate of cerebral hemorrhage 
is relatively higher than those in Western countries. However, 
dyslipidemia is an important risk factor in cerebral infarction, 
especially in atherosclerotic cerebral infarction, and many clinical 
studies revealed that the risk of stroke could be decreased through 
statin therapy.
1) Primary prevention 
Statin therapy in adults with CVD or in those with a high 
risk for CVD is effective for the primary prevention of cerebral 
infarction.80) The effects of other lipid-lowering agents on the 
primary prevention of stroke are still uncertain.
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2) Secondary prevention 
Stroke patients have increased risk not only of recurrent stroke 
events but also of the development of CVDs such as myocardial 
infarction. The subtype of stroke plays an important role in statin 
therapy for the secondary prevention of stroke. Statin therapy is 
the most effective treatment for atherosclerotic cerebral infarction; 
however it might be harmful in those with cerebral hemorrhage.
If there are CVDs or equivalent risk factors (carotid artery disease, 
PAD, abdominal aneurysm, diabetes, etc.), statins should be used 
for the primary prevention of stroke. The LDL cholesterol target 
level can be determined according to general recommendations.
High-intensity statin therapy is recommended to prevent the 
recurrence of stroke in patients with atherosclerotic cerebral infarction 
or TIA and in those with an LDL cholesterol level of ≥100 mg/dL.18)81)
Even if the LDL cholesterol is <100 mg/dL without atherosclerotic 
cerebrovascular diseases, statin therapy is strongly recommended 
to improve dyslipidemia in patients with atherosclerotic cerebral 
infarction or TIA.
There are no sufficient data on the effects of other lipid-lowering 
agents on the secondary prevention of stroke.
2. Chronic kidney diseases 
1) Approach to dyslipidemia in patients with chronic kidney 
disease
It is evident that the CVD risk is increased in all patients with 
chronic kidney disease (CKD) regardless of the severity of renal 
dysfunction.82) However, there are insufficient studies on the 
usefulness of measuring lipid concentration, how to select the 
patients for treatment, and its effects.
It is less useful to measure the lipid concentration in evaluating 
the cardiovascular risk in patients with CKD. In general, higher LDL 
cholesterol is associated with a higher risk for CVD even in patients 
with CKD; however, in patients with advanced CKD, who are at a 
very high risk for CVD, the LDL cholesterol level could be rather low 
owing to coexisting inflammation or malnutrition. Therefore, there 
are limitations in determining whether to start treatment on the 
basis of the LDL cholesterol level. 
For an adult with a newly diagnosed CKD (including those with 
dialysis and transplantation), lipid profiling should be conducted, 
including total cholesterol, HDL cholesterol, triglycerides, and 
LDL cholesterol, whereas the follow-up test timing, interval, and 
method should be determined according to the patient’s status. 
2) Cholesterol-lowering medication in patients with chronic 
kidney disease
CKD is considered to have an equivalent risk to CAD, and LDL 
reduction is the primary target of therapy.3)82)
As subgroup analyses of large clinical studies reported a 
preventive effect,83–85) statin monotherapy or statin/ezetimibe 
combination therapy is recommended in patients with CKD who are 
not currently subject to chronic dialysis therapy or those without 
renal transplantation. 
As there was no preventive effect reported in patients with CKD 
requiring chronic dialysis therapy,85–87) statin or statin/ezetimibe 
combination therapy should not be newly started in those patients. 
If patients with CKD requiring chronic dialysis therapy already 
have received statin or statin/ezetimibe combination therapy at the 
time of starting dialysis, such treatment can be maintained because 
a significant beneficial effect was observed in study subjects who 
did not receive dialysis therapy at the time of research enrollment 
but started dialysis during the research period, from a subgroup 
analysis of a large-scale study.85)
There is insufficient data about the safety of high-dose statin 
therapy in patients with CKD and a glomerular filtration rate of <60 
mL/min/1.73 m2. It is recommended to treat with the same dosage 
as that used in clinical studies, as these patients are at a high risk for 
potential adverse effects. As decrease in LDL cholesterol and better 
clinical outcomes were observed in some Asian studies even with 
relatively lower dosage, lower-dose treatment should be considered. 
3) Triglyceride-lowering medication in patients with chronic 
kidney disease
To improve hypertriglyceridemia in adults with CKD, including 
patients requiring chronic dialysis therapy and those who had 
undergone renal transplantation, therapeutic lifestyle modification is 
recommended. It was reported that fibric acid treatment is associated 
with an increase in serum creatinine level, related hospitalizations, 
and nephrologist consultations.88) On the basis of those evidences, it 
is not currently recommended to use fibric acid in patients with CKD 
for the purpose of lowering cardiovascular risks.
4) Summary
In reality, there is no consistent answer yet with respect to the 
effects of statin in patients with CKD. Such controversy is directly 
due to the shortage of high-quality large-scale studies in patients 
with CKD. Since the mid-2000s, several large-scale research 
results have been announced, based on which the guidelines on 
dyslipidemia in patients with CKD were published in 2013 by the 
Kidney Disease: Improving Global Outcomes.89)
3. Diabetes
Patients with type 2 diabetes have a 2–3-fold increased risk for 
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cardiovascular mortality than those without diabetes. Therefore, 
dyslipidemia should be aggressively treated in patients with 
type 2 diabetes.90)91) The typical pattern of diabetic dyslipidemia 
is hypertriglyceridemia and reduced HDL cholesterol levels. In 
addition, even though LDL cholesterol level is not elevated, it is more 
susceptible to atherosclerosis with more small dense LDL particles. 
Therefore, it is recommended to measure the blood lipid profile in 
patients with diabetes at the time of the first diagnosis and annually 
thereafter. Besides lipid profile (total cholesterol, HDL cholesterol, 
LDL cholesterol, and triglycerides), it is helpful to evaluate diabetic 
dyslipidemia by measuring the non-HDL cholesterol or apo B level.
The representative study on whether to use statins for primary 
prevention in patients with type 2 diabetes is Collaborative 
Atorvastatin Diabetes Study.92) As a result of administering 10 mg 
atorvastatin to patients with type 2 diabetes aged 40–75 years 
and with one or more cardiovascular risk factors, the average LDL 
cholesterol was 72 mg/dL, which was reduced by 39% compared 
with the baseline, whereas the risk of CVD was reduced by 37%. 
The meta-analysis also reported that statins decreased CVD by up 
to 20% in patients with type 2 diabetes when LDL cholesterol was 
reduced by 1 mmol/L (38 mg/dL), regardless of the baseline LDL 
cholesterol level.30)
In patients with type 2 diabetes, the first priority of dyslipidemia 
treatment is to lower LDL cholesterol to <100 mg/dL. In addition, it 
is recommended to maintain HDL cholesterol at ≥40 mg/dL in men 
and at ≥50 mg/dL in women, and triglycerides at <150 mg/dL. 
This guideline for the management of dyslipidemia classifies 
patients with CVD as very high-risk patients regardless of 
diabetes, and recommends more aggressive treatments to control 
LDL cholesterol. For patients with diabetes without CVD, it is 
recommended to lower LDL cholesterol to <100 mg/dL. 
Patients with diabetes and dyslipidemia should be educated 
about intensive lifestyle modification.
Statins are recommended first, not only for secondary prevention 
but also for the primary prevention of CVD in patients with type 2 
diabetes.
There is a lack of evidence on the effect of dyslipidemia 
medications other than statins (omega-3 fatty acids and niacin), 
owing to insufficient data, especially in domestic studies.
4. The elderly
The prevalence and mortality of CVD are expected to continuously 
increase because of the increase in the population of elderly persons, 
especially the very elderly. In particular, the prevalence of dyslipidemia 
increases in the elderly, who are a high-risk group for CAD, and for 
whom lipid-lowering therapy will provide many benefits.
The 2013 ACC/AHA guidelines recommend using statins 
continuously if a person >75 years old has already used it without 
adverse effects. Use of moderate-intensity statin is recommended, 
but for secondary prevention. High-intensity statin therapy might 
not be applicable to the elderly, owing to limited data.4) Statin 
therapy for primary prevention among the elderly should be 
determined after considering the comorbidities, safety issues, and 
priorities of care.
Meanwhile, the ESC/EAS guidelines recommended using statins 
for the young and the elderly because there was no difference 
in risk reduction both for primary and secondary prevention. It 
also recommended to exercise care concerning drug interactions 
and the adverse effects of statins, because many patients have 
concomitant diseases or take multiple other drugs.3) 
1) Primary prevention 
Statins can be beneficial for primary prevention in the elderly 
people because it was reported to significantly reduce the incidence 
of CVD and the cardiovascular mortality.66)
2) Secondary prevention 
Statin therapy is known to be useful in elderly patients with CVD, 
with fewer adverse effects than those in young adults.93) The use of 
statins in elderly patients is considered to be cost-effective.
3) Safety and drug interaction
For elderly patients, the risk of adverse drug reactions caused 
by statin should be considered. No significant increase in adverse 
drug reactions has been reported in elderly patients, including 
rhabdomyolysis and elevated hepatic enzymes; thus, statin can be 
used safely also in elderly patients.
Statin tends to be less used in elderly patients who require statin 
therapy owing to concerns about safety and efficacy issues. There 
are many studies supporting the effect of statins on the primary 
and second prevention of CVD in the elderly. In particular, the 
cost-effectiveness of statin therapy is more prominent in elderly 
patients as they have a higher risk of CVD than young adults.
There are insufficient data on the usefulness and safety issues in 
the very elderly (≥80 years old), and on whether aggressive lipid-
lowering therapy with high-dose statins is helpful in the elderly.
5. Children and adolescents
1) Definitions 
The definitions of dyslipidemia in children and adolescents are 
showed in Table 5-1.
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2) Blood lipid screening test 
If a blood lipid screening test is conducted in children who have 
a history of premature CAD or dyslipidemia, it will lead to missing 
30–60% of children with dyslipidemia. Therefore, the blood lipid 
profile should be routinely screened even when there is no clinical 
or family history.
As total cholesterol and LDL cholesterol decrease by 10–20% 
during adolescence, the blood lipid profile should be screened 
routinely in children aged 9–11 years. Non-HDL cholesterol is used 
for screening the blood lipid profile in children and adolescents.
If children or adolescents have a family history of premature CAD 
or cardiovascular risk factors, they are considered to have a high 
risk of developing dyslipidemia, and their blood lipid profile should 
be screened, as shown in Table 5-2.
3) Treatment of dyslipidemia 
Dyslipidemia treatments consist of nonpharmacological and 
pharmacological therapy, with the priority placed on aggressive 
nonpharmacological therapy and lifestyle modification. Lifestyle 
modifications include diet therapy, smoking cessation, and 
Table 5-2. Recommendations for blood lipid screening test by age 
　 Ages (years)
0-2 2-8 9-11 12-16 17-21













HDL: high density lipoprotein
TG ≥200 mg/dL or
TG ≥170 mg/dL+risk factors 
LDL-C ≥130 to -159 mg/dL+
family history of CAD/CVD risk factors 
LDL-C ≥130, <250 mg/dL 
TG ≥130, <500 mg/dL (age 10-19 years)
TG ≥100, <500 mg/dL (age <10 years)
LDL-C >250 mg/dL
TG ≥500 mg/dL (age >10 years)
LDL-C >130 mg/dL
TG <200 mg/dL 
→ Add secondary medication
TG >200-499 mg/dL
1. LDL-C ≥190 mg/dL
2. LDL-C >160 to -189 mg/dL+family history 
of CAD/CVD risk factors
3. LDL-C ≥130 to -159 mg/dL+diabetes of CVD
FU every 6 months
New cardiovascular risk factor evaluation
Maintain diet therapy+lifestyle modifocation
FLP test every 2-4 weeks
+diet therapy+life style modication
Perform FLP test twice on average
Consider pharmacotherapy
+lifestyle modication+diet therapy
Consider statin and/or omega-3 oil
FU every 3 months
Monitoring for pharmacotherapy
1. Observe growth and development
2. provide education about adverse drug effects
3. FPL, ALT, and AST tests
4. Check maintaining medication
5. Evaluation of CVD risk factors on a regular basis
Evaluation for secondary causes
Evaluation for other CVD risk factors
Lifestyle modication for 6 months+diet therapy
Fig. 5-1. Diagnosis and treatment algorithm in children and adolescents with high LDL cholesterolemia and hypertriglyceridemia. TG: triglyceride, 
FLP: fasting lipid profile, LDL-C: low density lipoprotein cholesterol, CAD: coronary artery disease, CVD: cardiovascular disease, FU: follow up, ALT: alanine 
transaminase, AST: aspartate transaminase.
Table 5-1. Definitions of dyslipidemia in children and adolescents (II, B)94)
Unit (mg/dL) Acceptable Borderline Abnormal
Total cholesterol <170 170-199 ≥200
LDL cholesterol <110 110-129 ≥130
Non-HDL cholesterol <120 120-144 ≥145
Triglycerides
Age 0-9 years <75 75-99 ≥100
Age 10-19 years <90 90-129 ≥130
HDL cholesterol >45 40-45 <40
LDL: low density lipoprotein, HDL: high density lipoprotein
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exercise; moreover, education should be aggressively provided to 
children and their family.
(1) Diet95) 
For step 1 (diet therapy), fat should be maintained at about 30% 
of the total calorie for normal growth and development, whereas 
the saturated fat intake should be limited to <10% and the total 
cholesterol intake should be limited to <300 mg (CHILD1 diet).
If the goal is not reached, step 2 diet therapy (saturated fat intake <7%, 
total cholesterol intake <200 mg daily, trans fat intake <1%, unsaturated 
fat intake of about 10%) should be conducted (CHILD2-LDL diet).
If the triglycerides increase, monosaccharide intake should be 
reduced and weight should be reduced. CHILD2-TG diet therapy 
should be conducted.
(2) Lifestyle modifications
It is recommended to perform exercises with an appropriate 
intensity on a regular basis, to maintain the proper BMI, as well 
as to quit smoking with the establishment of an environment for 
smoking prevention.
(3) Pharmacological therapy96)
If lifestyle modification has been tried for at least 6 months but 
failed in children and adolescents with dyslipidemia, it is possible 
to consider medication after evaluating the LDL cholesterol level 
and the cardiovascular risk level. The fasting blood lipid profile is 
tested at least twice or at 2 weeks to 3 months interval, to evaluate 
the need for medication. Medication can be started in children 
aged 10 years or older in general, except for special cases. The LDL 
cholesterol goal is at least ≤130 mg/dL in children and adolescents.
Medication should be started under the following conditions:
①If LDL cholesterol is ≥190 mg/dL in children aged 10 years or 
older who conducted lifestyle modification for >6 months;
②If LDL cholesterol is 160-189 mg/dL in children aged 10 years 
or older who conducted lifestyle modification for >6 months and 
have a risk for CVD (if there is a family history of premature CAD, or 
at least two or more risk factors of CVD). 
If the LDL cholesterol is 130-190 mg/dL in children ≥10 years old 
and not at a risk for CVD, lifestyle modification and controlling BMI 
under the 85th percentile are recommended.
For medication, adverse effects should be evaluated on a regular 
basis. The safety issue about long-term statin therapy in children 
and adolescents has not been well established yet.
Medication may be considered according to the level of LDL 
cholesterol, presence of CVD risk factors or family history of 
premature CAD. Medication may be started with statins or fibrate 
in patients with the TG level >500mg/dL (Fig. 5-1).
6. Familial hypercholesterolemia 
The incidence of heterozygous familial hypercholesterolemia 
(FH) is reported to be 1 per 500 people in Western studies. The 
most common cause is a mutation of LDL receptor genes, rarely 
caused by apo B or PCSK9 gene mutation. The LDL cholesterol level 
is about 200–400 mg/dL in adulthood, whereas the triglyceride 
level is usually normal, or elevated in some cases. If not treated, 
half of the male patients and 15% of the female patients might die 
at the age of about 60 years; however, there is no difference in life 
expectancy with early treatment.3)97)
1) Diagnosis
FH should be suspected in a patient with a family history of 
premature CAD in <50 year-old males or in f<60 year-old female or 
those with a history of FH. Secondary causes of hypercholesterolemia 
should be ruled out. For the diagnosis, the clinical criteria or DNA 
analysis is used, and the clinical criteria for diagnosis include the 
Simon Broome criteria (Table 5-3),98) Dutch criteria,99) and MED/PED 
criteria.100) It might be identified even in patients without clinical 
signs such as tendon xanthoma. If a patient has been found to have 
heterozygous FH, cascade family screening is recommended. 
Table 5-3. Simon Broome criteria for the diagnosis of FH
Definite FH 
When at least one of the following criteria is satisfied:
1)  Cholesterol concentration criteria are met and with the presence of tendon xanthoma in the patient or in first-degree* or  
 second-degree relatives 
2) DNA-based evidence of an LDL receptor mutation, familial defective apo B-100, or a PCSK9 mutation is present
Possible FH 
When the cholesterol criteria† are met and at least one of the following criteria is satisfied:
1) Family history of myocardial infarction: in a second-degree relative aged <50 years or in a first-degree relative aged <60 years
2)  Family history of hypercholesterolemia:  
 Total cholesterol >290 mg/dL in first- or second-degree relatives aged ≥16 years, or total cholesterol > 260 mg/dL in a child, or the  
 child’s brother or sister aged <16 years
*First-degree relatives: parents, siblings; second-degree relatives: grandparents, siblings of parents. †Cholesterol criteria: age younger than 16 years, total 
cholesterol >260 mg/dL, or LDL cholesterol >155 mg/dL; age 16 years or older, total cholesterol >290 mg/dL, or LDL cholesterol >190 mg/dL
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2) Treatment
General considerations: Heterozygous FH management includes 
the lifestyle modifications, lipid-lowering medication, and tests for 
atherosclerotic disease. Diet therapy and avoidance of smoking are 
important lifestyle modifications. Aggressive medication therapy 
is needed but should be administered with caution in women with 
a childbearing potential. To decide medication, combined drugs, 
comorbidities, and adverse effects should be considered, and 
patients and their family members should be informed of the fact 
that medication must be continued lifelong. High-dose statin is 
recommended first, and then ezetimibe can be used in combination 
or alone when LDL cholesterol level fails to reach the target level 
with statin alone or when adverse effects occur.
Target goal of treatment: The goal of LDL cholesterol is same 
as that in patients with a high risk for CVD. However, a maximal 
reduction of LDL cholesterol that can be achieved without adverse 
effects should be the target because it is usually difficult to lower 
the level to <70 mg/dL in FH, even with the maximum dosage of 
medication. It is reasonable to lower the LDL cholesterol by ≥50% 
from the baseline.3)4) 
7. Pregnancy
1) Lipid metabolism during pregnancy
(1) Changes in lipid metabolism during pregnancy
Lipids in plasma during pregnancy decrease at the first stage, 
and then begin to increase after 8 weeks of pregnancy. In the first 
and second trimesters, fat accumulates owing to increased appetite 
and lipogenesis; however, fat accumulation decreases during the 
third trimester owing to the increase in lipolysis and decrease in 
lipoprotein lipase activity.101
In the later period of pregnancy, insulin resistance increases 
lipolysis, glyconeogenesis, and ketogenesis in the fasting state in 
pregnant women. Insulin increases the activity of lipoprotein lipase 
in adipose tissue and reduces the activity of hormone-sensitive 
lipase, which is a lipolytic enzyme. In addition, insulin inhibits 
hepatic gluconeogenesis and ketogenesis. Peripheral insulin 
resistance develops in women with gestational diabetes and plays 
a role in increasing blood nonessential fatty acids and ketone body 
concentration.102
(2) Hyperlipidemia during pregnancy
In the later period of pregnancy, triglycerides, phospholipids, 
and cholesterol increase. In particular, the increase of triglycerides 
is most prominent. Whereas HDL cholesterol increases in the 
12th week of pregnancy due to the increase of estrogen, the 
total cholesterol and LDL cholesterol increase in the second and 
third trimesters. Triglycerides increase in VLDL. During pregnancy, 
hepatic lipase decreases the size of triglyceride-rich LDL cholesterol 
and increases its density. Such changes damage endothelial cells 
and cause atheroma formation.
2) Treatment of dyslipidemia during pregnancy
(1) Lifestyle modifications
Physical activity is effective in preventing gestational diabetes 
and gestational hypertension. The average triglyceride level, of any 
kind, is lower in women who are physically active. For diet therapy, 
it is difficult to make a clear conclusion yet, and additional studies 
are required.
(2) Omega-3 fatty acid 
Omega-3 fatty acids belong to the elements of diet, and 
they are not considered to increase the adverse effects during 
pregnancy. There are insufficient data to recommend omega-3 
fatty acid supplements instead of fish intake to normal pregnant 
women. However, supplementation of docosahexaenoic acid is 
recommended in pregnant women who do not usually eat fish at all.
(3) Statins 
Statins are contraindicated during pregnancy. Statins are not 
thought to increase fetal anomalies during pregnancy. Statin 
therapy is not recommended during pregnancy because there is 
no evidence that dyslipidemia treatment is beneficial to pregnant 
women or that cholesterol is required for the growth of embryo 
during pregnancy. A woman who is planning pregnancy or is 
already pregnant, should stop statins, if she is taking statins.
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